Mind Medicine (MNMD) Stock Forecast & Price Target

Compare

1,861 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MNMD Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Mind

Medicine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MNMD Stock 12 Month Forecast

Average Price Target

$26.00

▲(160.26% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Mind Medicine in the last 3 months. The average price target is $26.00 with a high forecast of $55.00 and a low forecast of $16.00. The average price target represents a 160.26% change from the last price of $9.99.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","17":"$17","30":"$30","43":"$43","56":"$56"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,17,30,43,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.44,12.021538461538462,15.603076923076923,19.184615384615384,22.76615384615385,26.347692307692306,29.92923076923077,33.510769230769235,37.09230769230769,40.673846153846156,44.255384615384614,47.83692307692308,51.41846153846154,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.44,9.79076923076923,11.141538461538461,12.492307692307692,13.843076923076923,15.193846153846154,16.544615384615383,17.895384615384614,19.246153846153845,20.596923076923076,21.947692307692307,23.298461538461538,24.64923076923077,{"y":26,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.44,9.02153846153846,9.603076923076923,10.184615384615384,10.766153846153845,11.347692307692308,11.929230769230768,12.510769230769231,13.092307692307692,13.673846153846153,14.255384615384616,14.836923076923076,15.418461538461539,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$55.00

Average Price Target$26.00

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$55

Buy

450.55%

Upside

Reiterated

08/04/25

MindMed's Strategic Advancements and Strong Leadership Underpin Buy Rating with $55 Price TargetWe assess MindMed using a discounted cash flow (DCF)-based valuation methodology. We assign a probability of success for MM120 of 75% in GAD, and 55% in MDD. We model annual gross equity raises of $100M-$150M in 2026E and 2027E, which could dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $4.2B and a $55 price target.

Jason WittesRoth MKM

Roth MKM

$36

Buy

260.36%

Upside

Reiterated

08/04/25

Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM)

Jay OlsonOppenheimer

Oppenheimer

$25

Buy

150.25%

Upside

Upgraded

08/04/25

Oppenheimer resumes MindMed (MNMD) at OutperformOppenheimer analyst Jay Olson resumes coverage on MindMed (NASDAQ: MNMD) with a Outperform rating and a price target of $25.00.

Michael OkunewitchMaxim Group

Maxim Group

$18

Buy

80.18%

Upside

Reiterated

08/04/25

MindMed: Positioned for Success in the Psychedelic Medicine Revolution with Strong Financials and Strategic Advancements

Marc GoodmanLeerink Partners

Leerink Partners

$20

Buy

100.20%

Upside

Reiterated

08/01/25

Mind Medicine's Promising Pipeline and Financial Stability Drive Buy Rating

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$16

Buy

60.16%

Upside

Reiterated

08/01/25

Canaccord Genuity Keeps Their Buy Rating on Mind Medicine (MNMD)

Rudy LiChardan Capital

Chardan Capital

$20

Buy

100.20%

Upside

Reiterated

08/01/25

Mind Medicine (MNMD) Receives a Buy from Chardan CapitalWe update our model based on the 2Q print and 10-Q filing, and we reiterate our Buy rating and $20 PT.

Brian AbrahamsRBC Capital

RBC Capital

$21

Buy

110.21%

Upside

Reiterated

07/31/25

RBC Capital Sticks to Their Buy Rating for Mind Medicine (MNMD)

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$23

Buy

130.23%

Upside

Reiterated

07/11/25

Evercore ISI Sticks to Its Buy Rating for Mind Medicine (MNMD)

Unknown AnalystCantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

05/29/25

Mind Medicine (MNMD) Receives a Buy from Cantor Fitzgerald

Joel BeattyRobert W. Baird

Robert W. Baird

$27→$16

Buy

60.16%

Upside

Reiterated

03/07/25

Mind Medicine price target lowered to $16 from $27 at BairdMind Medicine price target lowered to $16 from $27 at Baird

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$55

Buy

450.55%

Upside

Reiterated

08/04/25

Jason WittesRoth MKM

Roth MKM

$36

Buy

260.36%

Upside

Reiterated

08/04/25

Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM)

Jay OlsonOppenheimer

Oppenheimer

$25

Buy

150.25%

Upside

Upgraded

08/04/25

Oppenheimer resumes MindMed (MNMD) at OutperformOppenheimer analyst Jay Olson resumes coverage on MindMed (NASDAQ: MNMD) with a Outperform rating and a price target of $25.00.

Michael OkunewitchMaxim Group

Maxim Group

$18

Buy

80.18%

Upside

Reiterated

08/04/25

MindMed: Positioned for Success in the Psychedelic Medicine Revolution with Strong Financials and Strategic Advancements

Marc GoodmanLeerink Partners

Leerink Partners

$20

Buy

100.20%

Upside

Reiterated

08/01/25

Mind Medicine's Promising Pipeline and Financial Stability Drive Buy Rating

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$16

Buy

60.16%

Upside

Reiterated

08/01/25

Canaccord Genuity Keeps Their Buy Rating on Mind Medicine (MNMD)

Rudy LiChardan Capital

Chardan Capital

$20

Buy

100.20%

Upside

Reiterated

08/01/25

Mind Medicine (MNMD) Receives a Buy from Chardan CapitalWe update our model based on the 2Q print and 10-Q filing, and we reiterate our Buy rating and $20 PT.

Brian AbrahamsRBC Capital

RBC Capital

$21

Buy

110.21%

Upside

Reiterated

07/31/25

RBC Capital Sticks to Their Buy Rating for Mind Medicine (MNMD)

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$23

Buy

130.23%

Upside

Reiterated

07/11/25

Evercore ISI Sticks to Its Buy Rating for Mind Medicine (MNMD)

Unknown AnalystCantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

05/29/25

Mind Medicine (MNMD) Receives a Buy from Cantor Fitzgerald

Joel BeattyRobert W. Baird

Robert W. Baird

$27→$16

Buy

60.16%

Upside

Reiterated

03/07/25

Mind Medicine price target lowered to $16 from $27 at BairdMind Medicine price target lowered to $16 from $27 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mind Medicine

1 Month

xxx

Success Rate

7/12 ratings generated profit

Average Return

+8.58%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +8.58% per trade.

3 Months

xxx

Success Rate

6/8 ratings generated profit

Average Return

+17.30%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +17.30% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

17/22 ratings generated profit

Average Return

+54.44%

reiterated a buy rating 5 days ago

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 77.27% of your transactions generating a profit, with an average return of +54.44% per trade.

2 Years

xxx

Success Rate

12/12 ratings generated profit

Average Return

+100.27%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +100.27% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MNMD Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MNMD has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MNMD average Analyst price target in the past 3 months is 26.00.

Each month's total comprises the sum of three months' worth of ratings.

MNMD Financial Forecast

MNMD Earnings Forecast

Next quarter’s earnings estimate for MNMD is -$0.50 with a range of -$0.58 to -$0.46. The previous quarter’s EPS was -$0.50. MNMD beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 49.57% of the time in the same period. In the last calendar year MNMD has Outperformed its overall industry.

No data currently available

MNMD Sales Forecast

Next quarter’s sales forecast for MNMD is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MNMD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.20% of the time in the same period. In the last calendar year MNMD has Preformed in-line its overall industry.

MNMD Stock Forecast FAQ

What is MNMD’s average 12-month price target, according to analysts?

Based on analyst ratings, Mind Medicine’s 12-month average price target is 26.00.

What is MNMD’s upside potential, based on the analysts’ average price target?

Mind Medicine has 160.26% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MNMD a Buy, Sell or Hold?

Mind Medicine has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mind Medicine’s price target?

The average price target for Mind Medicine is 26.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.00 ,the lowest forecast is $16.00. The average price target represents 160.26% Increase from the current price of $9.99.

What do analysts say about Mind Medicine?

Mind Medicine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of MNMD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Mind Medicine (MNMD) Stock Forecast & Price Target

MNMD Analyst Ratings

MNMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mind Medicine

MNMD Analyst Recommendation Trends

MNMD Financial Forecast

MNMD Earnings Forecast

MNMD Sales Forecast

MNMD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts